A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jul 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2023 Results assessing the efficacy of nivolumab-based therapy in patients with relapsed or refractory primary large B-cell lymphoma of immune-privileged sites and diffuse large B-cell lymphoma with secondary CNS involvement, presented at the 28th Congress of the European Haematology Association.
02 Nov 2021 Status changed from active, no longer recruiting to completed.
05 Feb 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record. (Global end date: 2020-11-24)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com